SOSV is a global venture capital firm founded in 1995 and headquartered in Princeton, New Jersey. Specializing in seed-to-growth stage investments, SOSV operates multiple accelerator programs worldwide, including HAX for hardware, IndieBio and RebelBio for life sciences, Chinaccelerator and MOX for cross-border internet ventures, Food-X for innovative food solutions, and dlab for blockchain technology. The firm focuses on investments in revolutionary deep technologies aimed at improving human and planetary health, as well as cross-border markets, particularly in Asia. SOSV invests in approximately 150 startups annually, providing support through its resources to accelerate product development and scaling. Over its two-decade history, SOSV has established a strong reputation, consistently ranking among the top venture capital firms globally.

RA Capital Management, L.P. is a Boston-based venture capital firm that specializes in early and multi-stage investments in the healthcare and life sciences sectors. Founded in 2001, the firm focuses on companies developing drugs, medical devices, diagnostics, and biotechnology. RA Capital invests in a range of funding stages, from seed funding to later rounds, and is known for its willingness to invest under $1 million in initial rounds or larger sums in established companies. The firm's investment strategy emphasizes companies with promising technologies and products, particularly in areas like prevention, cost-effective diagnostics, genetic testing, and personalized medicine. The team consists of professionals with backgrounds in biology, chemistry, and medicine, enabling them to provide valuable insights into data, regulatory processes, and market demands. Additionally, RA Capital often seeks to co-invest and take board positions in its portfolio companies, enhancing their strategic growth opportunities.

Perceptive Advisors LLC is an investment management firm founded in 1999 and headquartered in New York City, with an additional office in Boston. The firm specializes in the healthcare sector, focusing on biotechnology, pharmaceuticals, life sciences, diagnostics, digital health, medical devices, and healthcare services. It engages in venture capital and incubation, investing at various stages of a company's life cycle, including seed and Series A funding, as well as late-stage venture and public market investments. Perceptive Advisors employs a long/short equity strategy and utilizes hedging techniques, including equity options and index options, while conducting in-house research to inform investment decisions. The firm also manages separate client-focused equity portfolios and provides customized debt financing solutions through its Perceptive Credit Opportunities Fund. Its clientele includes institutional investors, financial institutions, investment funds, and high-net-worth individuals.

OrbiMed Advisors LLC is a healthcare-focused investment firm founded in 1989, headquartered in New York City, with additional offices in various global locations. The firm manages approximately $5 billion in assets and specializes in private equity and venture capital investments across the healthcare sector, including pharmaceuticals, biotechnology, medical devices, and healthcare services. OrbiMed invests in companies at various stages, from early startups to established multinationals, and typically seeks to take majority stakes in its private equity investments. The firm employs fundamental analysis to guide its investment decisions and offers a range of financial services, including debt financing and structured capital, to both public and private healthcare companies. OrbiMed's investment strategy encompasses a broad spectrum of healthcare-related opportunities, targeting investments globally, primarily in North America, Europe, and Asia.

Alexandria Venture Investments, LLC is a venture capital firm established in 1996 and headquartered in Pasadena, California. As the strategic investment arm of Alexandria Real Estate Equities, it focuses on providing capital to seed, early-stage, and growth-stage companies within the healthcare sector. The firm emphasizes investments in biopharma, diagnostics, life sciences, research tools, agrifoodtech, and agtech. Alexandria Venture Investments aims to support innovative entities developing breakthrough technologies and therapies, leveraging its extensive industry knowledge and relationships with leading investors. Its approach is characterized by a commitment to fostering innovation and entrepreneurship in the life sciences and technology sectors.

Foresite Capital is a multi-stage investment firm specializing in healthcare and life sciences, managing $2 billion in assets. Established in 2011, the firm focuses on growth equity investments across various sectors, including pharmaceuticals, biotechnology, and healthcare technology. Foresite Capital employs a data-driven and scientific approach to its investment analysis, collaborating closely with portfolio companies through a multidisciplinary team of professionals, including scientists, engineers, analysts, and clinicians. This collaborative strategy aims to address significant unmet clinical needs by supporting promising businesses at different stages of their development. The firm places particular emphasis on companies that leverage data science and machine intelligence within the healthcare sector. Foresite Capital is headquartered in San Francisco, with an additional office in New York.

IndieBio is an accelerator firm established in 2014 and based in San Francisco, California, with an additional office in New York. It specializes in startups that utilize synthetic biology to address significant global challenges. IndieBio runs four-month accelerator programs aimed at both companies and teams with innovative ideas, focusing on seed-stage and early-stage investments. The firm typically invests $250,000, providing $50,000 in exchange for eight percent equity in biotech startups, with the possibility of an additional $25,000 as a convertible loan note. IndieBio prioritizes investments in businesses that leverage biology as the core of their technology, particularly in life sciences, biotechnology, and related fields. The firm favors teams with a minimum of two co-founders and is open to investing in startups from various geographical locations.

The National Science Foundation (NSF), established in 1950 and located in Alexandria, Virginia, is an independent federal agency dedicated to advancing fundamental research and education across all scientific and engineering disciplines. With an annual budget of approximately $7.8 billion, the NSF operates America's Seed Fund, which allocates nearly $200 million each year to support startups and small businesses through the Small Business Innovation Research (SBIR) program. This initiative provides non-dilutive funding of up to $1.5 million to assist in research and development efforts, thereby facilitating the transformation of scientific discoveries into commercially viable products and services. By helping to de-risk technology, the NSF plays a crucial role in fostering innovation and addressing societal challenges through scientific advancements.

Fidelity Investments, founded in 1946 and headquartered in Boston, Massachusetts, is a privately owned investment management firm that offers a wide range of financial services. These services include individual retirement accounts (IRAs), 401(k) rollovers, annuities, discount brokerage, retirement planning, estate planning, wealth management, and life insurance. The firm caters to individual investors, businesses, financial advisors, and institutions, managing equity, fixed income, and balanced mutual funds. Fidelity invests in global public equity and fixed income markets, employing in-house research to inform its investment decisions. The firm serves over 32 million individuals, assists more than 22,000 businesses in managing employee benefits, and provides support to over 13,000 financial institutions with innovative solutions. Fidelity operates through numerous regional offices and Investor Centers across the United States.

Casdin Capital, LLC is a New York-based investment firm established in 2012, specializing in the life sciences and healthcare sectors. The firm focuses on venture capital investments across various areas, including oncology, digital health, agtech, and broader healthcare. It operates as a Registered Investment Adviser and manages a long-short equity fund. Casdin Capital engages in both early-stage and late-stage private investments, utilizing a fundamental research approach to identify promising opportunities in its target industries. As of October 2020, the firm manages approximately $2.2 billion in assets. The founder and Chief Investment Officer, Eli Casdin, has been instrumental in shaping the firm’s investment strategy and direction.

Sequoia Capital, founded in 1972 and based in Menlo Park, California, is a prominent venture capital firm that invests in early to growth stage companies across various sectors, including technology, healthcare, financial services, and consumer services. The firm specializes in supporting startups and emerging growth companies, typically investing between $100,000 and $1 million in seed companies, $1 million to $10 million in early ventures, and $10 million to $100 million in growth investments. Sequoia Capital operates globally, with a presence in regions such as Israel, China, and Southeast Asia, and has built a diverse portfolio that includes notable companies like Airbnb, Alibaba, and JD.com. The firm emphasizes a partnership approach with entrepreneurs, leveraging decades of experience to guide them from initial concept through to public offering and beyond.

ARCH Venture Partners is a private equity and venture capital firm founded in 1986 and based in Chicago, Illinois. It specializes in investing in early-stage and later-stage technology companies, primarily focusing on life sciences, biotechnology, advanced materials, and various tech sectors such as clean technology, software, and communications. The firm is recognized for its role in commercializing innovations developed at academic research institutions and national laboratories. ARCH typically begins with conservative seed investments to mitigate risk, later leading or co-leading funding rounds up to liquidity. With a national scope and a regional focus, it targets underserved geographic markets and seeks to invest in companies addressing neurodegenerative diseases and mental health issues. ARCH has raised over $3 billion through ten venture funds and has invested in more than 150 companies, with a preference for co-founding partnerships with leading scientists and entrepreneurs. Its investors include major corporations, pension funds, and private investors.

T. Rowe Price Group, Inc. is a publicly owned investment management firm founded in 1937 and headquartered in Baltimore, Maryland. The company offers a diverse range of services, including separate account management, mutual funds, and sub-advisory services, catering to individuals, institutional investors, retirement plans, and financial intermediaries. T. Rowe Price manages investments in both public equity and fixed income markets globally, employing a combination of fundamental and quantitative analysis with a bottom-up investment approach. The firm also engages in socially responsible investing, focusing on environmental, social, and governance issues. In addition to traditional investment strategies, T. Rowe Price participates in late-stage venture capital investments, typically investing between $3 million and $5 million. The company operates numerous offices worldwide, reinforcing its commitment to delivering investment excellence over the long term.

Qiming Venture Partners is a prominent venture capital firm based in Shanghai, China, with additional offices in Beijing, Suzhou, and Hong Kong. Founded in 2006, the firm specializes in investing in early to growth-stage companies across various sectors, including healthcare, information technology, consumer products, media, and clean technology. Qiming has established itself as a leading investment firm in China, managing multiple funds with over $1 billion in assets. The firm focuses on supporting innovative entrepreneurs and companies that demonstrate high growth potential, particularly in the technology and healthcare landscapes. Through its strategic investments, Qiming aims to foster the development of new business models and technologies, contributing to the dynamic entrepreneurial ecosystem in China.

The Invus Group is a private equity firm based in New York, founded in 1985. It specializes in making direct and indirect investments in various stages of companies, focusing on special situations, venture capital, and growth equity. The firm manages an evergreen fund, which allows it significant flexibility in investment strategies and the types of companies it engages with, including those in consumer products, food, specialty retail, software, biotech, and medical devices. Invus emphasizes a tailored approach to each investment, recognizing the uniqueness of every business and the need for long-term commitment to foster transformation. The firm aligns its incentives with those of its partners and has a history of empowering owner-managers by reinvesting capital from a consistent group of European families. Invus operates from offices in New York, London, Paris, and Hong Kong and manages assets exceeding $4 billion.

Khosla Ventures is a venture capital firm established in 2004 by Vinod Khosla, co-founder of Sun Microsystems, and is headquartered in Menlo Park, California. The firm manages over $5 billion and focuses on investing in a diverse range of sectors, including consumer technology, enterprise solutions, education, healthcare, financial services, agriculture, sustainable energy, and robotics. Khosla Ventures provides not only capital but also strategic guidance to entrepreneurs, particularly in early-stage ventures, where it often supports innovative and unconventional projects. The firm seeks to back companies that are driven by breakthrough technologies, with investment sizes ranging from $100,000 to over $20 million. Khosla Ventures maintains a collaborative approach, frequently co-investing with other firms, including Kleiner Perkins, with which it has historical ties.

GV Management Company, LLC, formerly known as Google Ventures, serves as the venture capital arm of Alphabet Inc., established in 2009 and headquartered in Mountain View, California, with additional offices in Boston, New York, Cambridge, and London. The firm specializes in growth capital investments across various stages, including seed, early, mid, and late stages, focusing on sectors such as life sciences, healthcare, artificial intelligence, robotics, cyber security, and agriculture. GV has invested in over 300 companies, seeking to support startups that aim to innovate and transform industries. The firm typically invests up to $50 million, with smaller amounts allocated to early-stage ventures. GV provides its portfolio companies with exceptional support by connecting them with Google's resources and talent, leveraging a team of experts in engineering, design, science, and marketing to enhance their growth potential.

F Prime, Inc. is a venture capital firm based in Cambridge, Massachusetts, with additional offices in San Francisco and London. Founded in 1969, it has a strong legacy rooted in Fidelity Investments, which has been a significant player in asset management since 1946. F Prime focuses on early-stage investments in North America and Europe, primarily in the healthcare, life sciences, technology, therapeutics, fashion, medtech, and health information technology sectors. The firm operates several funds, including those dedicated to healthcare, oncology, life sciences, and health technology services. F Prime Capital Partners emphasizes supporting entrepreneurs without the pressure of external fundraising, allowing them to concentrate on identifying and nurturing promising companies.

Atlas Venture is a private equity and venture capital firm based in Cambridge, Massachusetts, founded in 1980. The firm specializes in early-stage investments, particularly in the life sciences and technology sectors, with a strong emphasis on biotechnology and personalized medicine. Atlas Venture adopts a seed-led venture creation strategy, rigorously selecting opportunities to build scalable businesses. It typically invests between $0.25 million and $15 million per transaction, preferring to be a lead investor and to obtain board representation in its portfolio companies. The firm primarily focuses on startups in the United States and Europe, particularly in New England and the San Francisco Bay Area. Since its inception, Atlas Venture has managed over $2 billion in committed capital and has been involved in the creation and growth of numerous companies, with many achieving significant exits through acquisitions or public offerings. The firm has distinct teams dedicated to life sciences and technology investments, allowing for specialized attention in these dynamic fields.

New Enterprise Associates, Inc. is a global venture capital and private equity firm based in Menlo Park, California, founded in 1977. The firm specializes in investments across various stages of company development, from seed and startup to later-stage growth and public investments. With over $19 billion in cumulative committed capital, NEA focuses on technology and healthcare sectors, particularly in areas such as consumer internet, financial technology, software, healthcare services, life sciences, and energy technology. The firm also invests in semiconductor companies and alternative energy initiatives in India. NEA has a proven track record, with more than 210 portfolio company IPOs and over 360 acquisitions. The firm's investment strategy encompasses a global perspective, targeting opportunities in North America, Asia, and South America, and typically involves investments ranging from $0.05 million to $20 million.

The Bill & Melinda Gates Foundation is an independent non-profit organization based in Seattle, Washington, founded in 2000. It focuses on addressing global inequities by promoting initiatives in education, health, and community support, particularly for low-income families in the Pacific Northwest. The foundation aims to improve health outcomes and alleviate extreme poverty worldwide, funding a variety of programs and strategies to achieve these goals. It operates regional offices in Washington, D.C.; New Delhi, India; Beijing, China; and London, United Kingdom. The foundation's trustees include co-founders Bill and Melinda Gates, along with Warren Buffett, who oversee its grant-making activities and strategic direction.

The EIC pilot supports top-class innovators, entrepreneurs, small companies and scientists with bright ideas and the ambition to scale up internationally. It brings together the parts of Horizon 2020 that provide funding, advice and networking opportunities for those at cutting edge of innovation.

Deerfield Management is a healthcare investment management firm founded in 1994 and based in New York. With over $8 billion in assets, Deerfield specializes in long-term structured investments across both public and private healthcare companies, including pharmaceuticals, biotechnology, life sciences, and healthcare technology. The firm typically holds equity or debt interests in more than 100 companies, ranging from early-stage drug research ventures to established healthcare service and medical device providers. Additionally, Deerfield is committed to philanthropy, donating a portion of its profits to the Deerfield Foundation. The Deerfield Institute employs various research methods to provide objective market intelligence, engaging with thousands of professionals annually to address complex healthcare issues.

5Y Capital is a private equity and venture capital firm based in Shanghai, China, focused on seed, start-up, early venture, and growth capital investments. Founded in 2008 and previously known as Morningside Venture Capital, the firm manages approximately USD 5 billion in dual-currency funds, supported by global investors such as sovereign wealth funds, family offices, and endowments. 5Y Capital primarily invests in various sectors, including healthcare, technology, fintech, media, software, life sciences, and education, with a special emphasis on medical treatment, biotechnology, and digital health. The firm seeks opportunities in China and other emerging markets across Asia and the Pacific, aiming to support entrepreneurs in building innovative companies. 5Y Capital typically makes initial investments exceeding USD 500,000 per portfolio company and operates as a subsidiary of Morningside Group, which has been active in venture capital investments since 1992.

Wellington Management Company LLP, founded in 1928 and headquartered in Boston, Massachusetts, is a prominent investment management firm providing comprehensive solutions to institutional clients worldwide. The firm specializes in a diverse range of investment strategies, including equity, fixed income, multi-asset, and alternative investments, tailored to meet the unique return and risk objectives of its clients. Wellington Management employs a collaborative approach, leveraging proprietary research and analytical tools to identify opportunities and manage risks across global capital markets. The firm caters to a wide array of clients, including sovereign institutions, endowments, foundations, wealth managers, and insurance companies, spanning more than 50 countries. With a focus on long-term investment principles, Wellington Management fosters independent thought and debate within its teams, ensuring that resources are effectively utilized to deliver consistent results. The firm also emphasizes environmental, social, and governance (ESG) considerations in its research and investment processes, engaging with companies on key ESG topics.

The Redmile Group, established in 2007 and based in San Francisco with an additional office in New York, is a private equity firm that focuses on venture capital investments in the healthcare sector. The firm manages multiple funds, including Redmile Biopharma Investments II and III, which are dedicated to investing in the biopharma and broader healthcare industries. Through these investments, Redmile Group aims to support innovative companies that are advancing healthcare solutions.

Illumina is a leading company focused on genomic analysis, providing advanced tools and services for the study of genetic material in life sciences and clinical laboratories. Established in 1998 in San Diego, California, Illumina generates over 90% of its revenue from sequencing instruments, consumables, and related services. Its high-throughput technology facilitates whole genome sequencing for humans and large organisms, while its lower throughput tools cater to applications like viral and cancer tumor screening. Additionally, Illumina offers microarrays for cost-effective genetic screening, primarily in consumer and agricultural sectors. The company emphasizes collaboration and rapid delivery of innovative solutions, which are essential for advancing personalized medicine. Through initiatives like Illumina Accelerator, established in 2014, the company supports startups in the genomic industry by providing mentorship, financial assistance, and access to essential resources, fostering a dynamic ecosystem for innovation in genomics.

Illumina Ventures is a venture capital firm established in 2016 and based in California, focusing on early-stage investments in life sciences and healthcare sectors. The firm operates in a strategic partnership with Illumina, which provides the majority of its capital and valuable expertise in genomics. Illumina Ventures primarily invests in companies pioneering advancements in nucleic acid sequencing, clinical diagnostics, therapeutics, and other applications of genomics to enhance human health. The firm typically targets seed, Series A, and Series B funding rounds and seeks to invest between $5 million and $10 million in promising startups. Its investment strategy encompasses a broad range of areas, including life science research, agriculture, environmental science, public safety, and personal wellness, often collaborating with other institutional and strategic investors to maximize impact.

Sofinnova Partners is an independent venture capital firm headquartered in Paris, France, with a focus on the life sciences sector. Established in 1972, the firm has financed nearly 500 companies over its 45-year history, primarily investing in start-ups, early-stage companies, corporate spin-offs, and occasionally turnaround situations. Sofinnova Partners actively sources investment opportunities, often taking the lead as the first institutional investor in Series A financings. The firm plays a significant role in guiding its portfolio companies, participating on their boards, and supporting them from the formation phase through to exit. While its primary investment focus is in Europe, the firm also makes select investments globally, concentrating on healthcare and sustainability sectors within life sciences, including biopharmaceuticals, biotech, medical devices, and industrial biotechnology.

SoftBank Investment Advisers is a venture capital firm based in London, United Kingdom, that specializes in growth equity and late-stage investments. It is a subsidiary of SoftBank Group Corp. The firm focuses primarily on the technology sector, targeting areas such as artificial intelligence, robotics, internet-of-things, telecommunications, computational biology, cloud technologies, fintech, consumer internet, and healthcare. SoftBank Investment Advisers typically invests a minimum of $100 million in both minority and majority stakes in private or public companies, with a strong emphasis on opportunities in the United States and globally. Established in 2017, the firm aims to leverage its operational expertise and extensive global network to foster innovation and drive growth in its portfolio companies.

Novo Holdings, established in 1999 and based in Copenhagen, is the asset manager for the Novo Nordisk Foundation, overseeing its wealth and investments. The company primarily focuses on the life sciences sector, investing across various stages of company development, from early-stage ventures to established firms. Novo Holdings also manages a diversified portfolio of financial investments, including equity and fixed income securities. It is recognized as a leading life science investor globally and aims to generate long-term value to support the Foundation's grant obligations for medical and scientific research. Additionally, it plays a pivotal role in the Novo Group, maintaining a significant influence over its associated companies, including Novo Nordisk and Novozymes, while ensuring compliance with the group’s shared values and management principles. Through initiatives like Novo Seeds, the firm supports early-stage applied research in Scandinavia, further solidifying its commitment to advancing health and welfare through strategic investments.

Innovate UK is a non-departmental public body established in 2007 and based in Swindon, United Kingdom. Funded by a government grant, it supports innovation in science and technology by providing funding services to businesses across various sectors and regions. The organization aims to drive productivity and economic growth by facilitating advancements that contribute to the UK’s economic landscape. In addition to funding, Innovate UK offers a range of services and information related to business and economic development, thereby fostering a supportive environment for innovation.

Mission BioCapital is a venture capital firm based in Cambridge, Massachusetts, specializing in investments in early-stage life science and biotechnology companies. Founded in 2009, the firm is recognized for its leadership team's extensive experience in investing in and launching numerous life science ventures. Mission BioCapital operates in regions known for their strong research and venture capital ecosystems, allowing it to leverage local expertise and networks. The firm is committed to providing comprehensive support to its portfolio companies, earning a reputation for its deep engagement and strategic guidance in the life sciences sector.

DCVC is a venture capital firm based in Palo Alto, California, founded in 2010. The firm specializes in investing in seed and early-stage companies across various sectors, including artificial intelligence, exascale computing, climate technology, engineering, materials science, robotics, space, water, biology, defense, and security. With a team of experienced venture capitalists, technology entrepreneurs, and engineers, DCVC has a proven track record, having invested in over 150 companies and achieved 40 significant exits. In 2018, the firm expanded its focus with the launch of DCVC Bio, which invests in early-stage startups in computational biology. This branch targets innovations in synthetic biology, medicine, and agriculture, emphasizing teams that leverage advancements in genetic sequencing, artificial intelligence, and automation to drive transformative changes in the life sciences. Both divisions of DCVC are committed to supporting entrepreneurs who are advancing technology and creating impactful solutions in their respective fields.

Northpond Ventures is a venture capital firm based in Bethesda, Maryland, with additional offices in San Francisco and Cambridge. Founded in 2018, the firm specializes in growth capital investments across various sectors, including life sciences, biotechnology, diagnostics, digital health, and emerging technologies. Northpond Ventures aims to support innovative companies that are poised to make significant advancements in healthcare and technology, with a focus on building a better future through its strategic investments. As a Registered Investment Adviser, the firm is committed to fostering developments in therapeutics, artificial intelligence, machine learning, and medical technology.

Flagship Pioneering, established in 2000 and based in Cambridge, Massachusetts, is a venture capital firm that focuses on creating and nurturing innovative companies in the fields of healthcare, biotechnology, life sciences, renewable energy, and agriculture. The firm emphasizes the development of first-in-category ventures designed to transform human health and promote sustainability. By combining scientific expertise with entrepreneurial leadership, Flagship Pioneering adopts an evolutionary approach to navigate from ambitious ideas to transformative outcomes. The firm is committed to attracting and cultivating top talent in science and management, positioning itself as a leader in advancing technologies that address critical global challenges.

Versant Ventures is a prominent healthcare investment firm founded in 1999 and headquartered in San Francisco, California. The firm focuses on investing in various sectors within healthcare, including biotechnology, pharmaceuticals, medical devices, and life sciences, and operates at all stages of company development. With $2.3 billion in assets under management, Versant Ventures emphasizes the discovery and development of innovative therapeutics, leveraging a team with substantial investment, operational, and scientific expertise to take a hands-on approach in building companies. The firm has a strong track record, with over 65 of its portfolio companies achieving successful acquisitions or public offerings. Versant maintains offices in Canada, the U.S., and Europe, allowing for a global investment reach.

Leaps by Bayer, founded in 2015 and headquartered in Leverkusen, Germany, is the corporate venture capital arm of Bayer. The firm focuses on making significant investments in groundbreaking advancements within the life sciences, particularly in biotechnology and agriculture. By targeting disruptive biotechnologies and scientific breakthroughs, Leaps by Bayer aims to drive innovations that could fundamentally improve global health and agricultural practices. The firm acknowledges the inherent challenges in pursuing such ambitious goals, including potential setbacks and failures, but remains committed to supporting transformative solutions that have the potential to create a lasting positive impact on humanity.

The Cystic Fibrosis Foundation, an independent non-profit organization based in Bethesda, Maryland, was established in 1955 with the mission to cure cystic fibrosis and enhance the quality of life for those affected by the disease. The foundation focuses on funding research and drug development, promoting individualized treatment approaches, and ensuring access to high-quality specialized care. As a leader in the pursuit of a cure, the foundation actively supports initiatives that advance scientific knowledge and therapeutic options for cystic fibrosis, ultimately striving to empower individuals with the disease to lead full and productive lives. The foundation's assets are managed by its executive management team to facilitate these goals effectively.

Takeda Ventures, Inc. is the venture capital arm of Takeda Pharmaceutical Company, focusing on investments in the healthcare and life sciences sectors. Established in 2001 and based in Palo Alto, California, the firm engages in both direct and fund-of-fund investing, targeting seed, startup, early, mid-stage, and mid-venture capital opportunities. Takeda Ventures emphasizes therapeutic innovation, particularly in areas such as cardiovascular diseases, chronic inflammatory and immune disorders, central nervous system conditions, metabolic disorders, gastroenterology, renal diseases, oncology, and regenerative medicine. The firm typically invests between $0.25 million and $5 million, preferring to take minority stakes while collaborating with other investors. Takeda Ventures does not invest in gene therapy, anti-infective products, medical devices, or diagnostics. It aims to facilitate therapeutic discovery alliances and foster synergies with Takeda's extensive R&D capabilities, supporting entrepreneurs and early-stage companies from preclinical development to clinical proof of concept. The firm primarily focuses its investments in the United States, Canada, and Europe.

Lilly Asia Ventures, founded in 2008, serves as the corporate venture capital arm of Eli Lilly and Company, focusing on investments in the life sciences and healthcare sectors, with a particular emphasis on opportunities in China. The firm targets promising companies at various stages of development, from seed to commercialization, and seeks to invest between $5 million and $15 million per round. Lilly Asia Ventures specializes in human therapeutics, medical technology, healthcare services, and broader life sciences, including industrial and agricultural biotechnology. With a preference for taking minority stakes, typically less than 20 percent, the firm aims to partner with companies that exhibit strong management teams and innovative business models. Headquartered in Shanghai, with additional offices in Hong Kong and California, Lilly Asia Ventures is committed to driving innovation in the healthcare landscape across East and South Asia.

Invitae is a genetic information company focused on improving healthcare through the integration of genetic information into routine medical practice. It specializes in genetic diagnostics for hereditary disorders, offering a comprehensive service that consolidates numerous genetic tests into a single platform. This approach aims to provide higher quality results with faster turnaround times and lower costs compared to traditional single-gene tests. Invitae's offerings encompass a wide range of genetic tests related to hereditary cancer, neurological disorders, cardiovascular conditions, pediatric disorders, and metabolic disorders. By making genetic testing more affordable and accessible, establishing a secure infrastructure for genome management, and fostering a collaborative community for sharing genetic information, Invitae seeks to advance both science and medicine, ultimately enhancing healthcare for a global population.

Agilent Technologies specializes in providing application-focused solutions within the life sciences, diagnostics, and applied chemical markets globally. The company operates through three main segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers a variety of analytical instruments, including chromatography systems and mass spectrometry equipment, alongside laboratory automation and analytical software. The Diagnostics and Genomics segment focuses on advanced genetic analysis tools, including DNA mutation detection and gene expression profiling, as well as quality control solutions for nucleic acid samples. The Agilent CrossLab segment supplies laboratory consumables, custom chemistries, and a range of support services aimed at optimizing laboratory operations. With a strong customer base across biopharmaceutical, environmental, academic, and government sectors, Agilent Technologies emphasizes collaboration and innovation to address evolving scientific needs. Headquartered in Santa Clara, California, the company utilizes multiple sales channels, including direct sales and electronic commerce, to reach its diverse clientele.

Fifty Years Industries, LLC is a venture capital firm founded in 2016 and based in San Francisco, California. The firm focuses on seed and early-stage investments in a variety of sectors, including synthetic biology, food technology, education, health, civic, community, energy, hardware, software, and robotics, without restricting itself to specific industries. Fifty Years aims to support founders who leverage technology to address significant global challenges, aligning its investments with the Sustainable Development Goals. The firm typically commits to investments for a duration of five years or more, primarily targeting companies in North America and Europe.

Bpifrance Financement S.A. is a French financial institution that provides a wide range of financing solutions and support services for businesses at various stages of their development. Established in 1980 and based in Maisons-Alfort, France, the company offers medium to long-term loans, export insurance, real estate and equipment leasing, and working capital loans. Bpifrance also invests in startups, small and medium-sized enterprises (SMEs), and mid-cap companies through direct investments and fund management activities. Additionally, it provides consulting services for executives and training for CEOs, aiming to facilitate innovation and growth. Bpifrance was formed from the merger of several entities in July 2013, including OSEO, CDC Entreprises, and FSI, to enhance its role in supporting the financing of the French economy.

Civilization Ventures is a venture capital firm founded in 2017 and based in San Francisco, California. The firm focuses on investing in innovative companies within the health tech and biology-driven sectors, including digital health, synthetic biology, diagnostics, 3D bio-printing, and AI-enabled health technologies. Civilization Ventures aims to be the first check and lead investor in disruptive startups, supporting visionary founders who are shaping the future of healthcare. The firm is managed by a team of experienced entrepreneurs and industry experts dedicated to ensuring the success of their portfolio companies.

Venrock is a venture capital investment firm founded in 1969 as the venture capital arm of the Rockefeller family. Based in Palo Alto, California, with an additional office in New York, the firm primarily invests in seed and early-stage companies in the technology and healthcare sectors. Venrock has a diverse investment focus that includes information technology, media, energy, life sciences, and emerging technologies. Over the years, the firm has built a notable portfolio, partnering with entrepreneurs to support the growth of successful companies such as Apple Computer, Athenahealth, and Gilead Sciences. Venrock continues its mission by identifying and nurturing innovative ventures that have the potential to create lasting impact within their respective industries.

EcoR1 Capital, LLC is an employee-owned investment firm based in San Francisco, California, established in 2012. The firm specializes in managing pooled investment vehicles and separate client-focused equity and fixed income portfolios. EcoR1 Capital primarily invests in the public equity markets of the United States, employing a long/short strategy. The firm focuses on the biotechnology sector, as well as the broader healthcare, life sciences, and oncology sectors. As a Registered Investment Adviser (RIA), EcoR1 Capital aims to generate returns for its clients through strategic investments in these fields.

The California Institute for Regenerative Medicine (CIRM) was established in 2005 after the approval of Proposition 71, which allocated $3 billion for stem cell research in California. This initiative aimed to enhance research capabilities at state universities and institutions by creating a dedicated agency for grant and loan distribution related to stem cell research and development. CIRM's mission focuses on advancing stem cell research and regenerative medicine, adhering to the highest ethical and medical standards. The organization seeks to foster the discovery and development of cures, therapies, diagnostics, and research technologies to alleviate human suffering caused by chronic diseases and injuries. CIRM has demonstrated its commitment to this mission by funding significant projects, including awarding over $13 million to support clinical trials that explore innovative treatment strategies.

Decheng Capital LLC is a private equity and venture capital firm established in 2012, with headquarters in Menlo Park, California, and additional offices in Shanghai and New York. The firm specializes in early-stage and growth-stage investments, primarily focusing on sectors such as life sciences, healthcare, biopharmaceuticals, medical devices, diagnostics, digital health, and agricultural biotechnology. Decheng Capital aims to support companies with innovative technologies and strong market positions, particularly in China. With over $1 billion in capital under management, the firm leverages its expertise and extensive network to create value for its portfolio companies and deliver returns for its investors.